Denali Therapeutics Financial Statements
NASDAQ: DNLIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 19.45 0.00%
Denali Therapeutics revenue and earnings
In fiscal 2025, Denali Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Denali Therapeutics reported a net loss of $512.5 million, compared with a loss of $422.8 million a year earlier. Diluted earnings per share came in at -$2.97.
Summary generated from market data by MetaCap's automated system. Methodology
Denali Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 330.53M | 108.46M | 48.66M | 335.66M | 26.68M | 129.16M | 0 | 0 |
| Revenue growth (YoY) | — | -100.00% | +204.74% | +122.90% | -85.50% | +1158.19% | -79.34% | — | — | — |
| Operating Expenses | 555.34M | 501.88M | 527.23M | 449.21M | 344.41M | 272.94M | 239.86M | 175.53M | 90.14M | 87.43M |
| Research & Development | 418.78M | 396.44M | 423.88M | 358.73M | 265.35M | 212.62M | 193.38M | 143.18M | 74.46M | 75.70M |
| Operating Income | -555.34M | -487.34M | -196.70M | -340.74M | -295.75M | 62.72M | -213.18M | -46.37M | -90.14M | -87.43M |
| Other Income (Expense) | — | — | 51.51M | 14.77M | 4.59M | 9.24M | 15.22M | 10.13M | 1.96M | 781.00K |
| Income Tax | 102.00K | 68.00K | 30.00K | 21.00K | -575.00K | 823.00K | -351.00K | 0 | 0 | — |
| Net Income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M | 71.14M | -197.61M | -36.24M | -88.19M | -86.65M |
| Net Income growth (YoY) | — | — | — | — | -508.49% | — | — | — | — | — |
| EPS (Basic) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | 0.65 | -2.07 | -0.39 | -5.89 | -13.49 |
| EPS (Diluted) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | 0.63 | -2.07 | -0.39 | -5.89 | -13.49 |
| Shares Outstanding (Basic) | 172.65M | 164.47M | 137.37M | 125.53M | 121.52M | 108.97M | 95.61M | 92.62M | 14.96M | 6.42M |
| Shares Outstanding (Diluted) | 172.65M | 164.47M | 137.37M | 125.53M | 121.52M | 112.70M | 95.61M | 92.62M | 14.96M | 6.42M |
| EBITDA | -544.16M | -479.55M | -179.97M | -330.36M | -287.16M | 71.25M | -205.19M | -38.96M | -87.06M | -85.96M |
| Operating Margin | — | — | -59.51% | -314.16% | -607.78% | 18.69% | -799.10% | -35.90% | — | — |
| Net Margin | — | — | -43.94% | -300.56% | -597.15% | 21.19% | -740.74% | -28.06% | — | — |
This table shows 10 annual periods of Denali Therapeutics's income statement, from FY 2025 back to FY 2016, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow DNLI's reporting calendar. What is a income statement?